Abivax reports Q1 2026 results, obefazimod shows sustained remission

May 22, 2026 4:05 PM

Abivax SA (Euronext: ABVX / NASDAQ: ABVX) reported first quarter 2026 financial results and interim data from its Study 108 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found